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Cefotetan-induced immune
hemolytic anemia following
prophylaxis for cesarean delivery
S. SHARIATMADAR, J.R. STORRY, L. SAUSAIS, AND M.E. REID
Second- and third-generation cephalosporins, notably cefotetan, are
increasingly implicated in severe, sometimes fatal immune-
mediated hemolytic anemia. We describe a 26-year-old woman who
developed severe hemolytic anemia 2 weeks after receiving a single
prophylactic dose of cefotetan during cesarean delivery. The
patient’s DAT was weakly reactive for IgG and her serum reacted
with cefotetan-coated RBCs. The antibody had a titer of 4096 by
antiglobulin testing.The patient required treatment with two units
of PRBCs and experienced gradual resolution of hemolysis. Our
case emphasizes the need for increased awareness of delayed onset
hemolytic anemia following prophylactic use of cefotetan.
Immunohematology 2004;20:63–66.
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Cefotetan is a second-generation cephalosporin
active against gram-positive and gram-negative aerobic
and anaerobic bacteria.1 Because of its broad-spectrum
antibacterial activity, cefotetan is a popular choice for
antimicrobial prophylaxis during surgical and obstetric
procedures.2 A single dose is commonly administered
after cesarean deliveries to reduce the incidence of
postpartum endomyometritis.3 Although short-term
prophylaxis with cefotetan is thought to carry minimal
adverse effects, several cases of severe hemolytic
anemia have been associated with the use of this drug,
some of which have been fatal.4–20 We present a case of
severe hemolytic anemia 2 weeks following cefotetan
prophylaxis for cesarean delivery.
Case Repor t
A healthy 26-year-old woman underwent an
uncomplicated cesarean delivery. Perioperatively, a
single prophylactic dose of cefotetan (1.0 g) was
administered intravenously. Her hospital course was
uneventful and she was discharged home in stable
condition. Routine laboratory work-up upon dis-
charge, including a complete blood count, was within
normal limits.
Two weeks following delivery, the patient returned
to the hospital complaining of fatigue and shortness of
breath. She had a significant anemia with Hct of 14.8
percent. Serum LDH was 750 IU/L; total bilirubin was
3.5 mg/dL, and direct bilirubin was 1.0 mg/dL. The
reticulocyte count was 15% (corrected 5.3%). A
peripheral blood smear revealed marked poly-
chromasia and nucleated RBCs. Other laboratory
studies, including platelet count, PT, aPTT, and serum
fibrinogen, were within normal limits. Serum blood
urea nitrogen, creatinine, haptoglobin, and liver
function studies were also normal. Urine, stool, and
blood cultures demonstrated no growth. The patient
was transfused with two units of PRBCs and exper-
ienced gradual resolution of hemolytic anemia.She was
discharged home in stable condition.
Mater ials and Methods
Routine serologic techniques were used. Drug
studies were performed as described by Arndt et al.19 A
40 mg/mL solution of cefotetan was prepared in PBS
(pH 7.1). One aliquot of washed PRBCs was incubated
with 10 volumes of the drug solution for 2 hours at
37°C. The RBCs were washed × 3 and resuspended to
a 5% solution. The patient’s serum was diluted 1 in 20.
Normal serum, tested in parallel, was also diluted 1 in
20. Two drops of the diluted serum were incubated
with one drop of untreated or cefotetan-treated RBCs
for 1 hour at 37°C. Tests were read after a brief
centrifugation and after IAT. Tests for reactivity by the
so-called immune complex mechanism were as
described.19 Titration studies were performed using
doubling dilutions of serum. An eluate was prepared
using the patient’s RBCs and the Elu-kit II (Gamma
Biologicals, Norcross, GA). Additional samples were
submitted for serologic investigation of drug-induced
hemolytic anemia.
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Results
No unexpected antibodies were detected using
antiglobulin techniques including albumin, LISS, PEG,
and MTS IgG gel cards (Micro Typing Systems,
Pompano Beach, FL). An acid eluate was nonreactive
with all cells tested by LISS, PEG antiglobulin testing,
and IgG gel card. The DAT was weakly positive using
anti-IgG and negative using anti-C3. There was
insufficient eluate to test against cefotetan-coated
RBCs. Further testing revealed anti-cefotetan in the
patient’s serum reacting with cefotetan-coated RBCs.
The antibody was strongly reactive and had a titer of
4096 by saline IAT. Test results were negative with
untreated RBCs when a 1mg/mL solution of cefotetan
was added to the serum (Table 1).
Discussion
Cefotetan is presently the most common cause of
drug-induced hemolytic anemia.19 A recent search of
the FDA’s spontaneous reporting system and theWorld
Health Organization’s database revealed 85 cases of
hemolytic anemia since the introduction of cefotetan
in 1985.20 Prior to this review, case and case series
reports involving 60 patients with hemolytic anemia
associated with this drug had been documented.4–19
Immune hemolytic anemia (IHA) secondary to
sensitization with cefotetan can result from several
types of interactions between the drug, antibodies, and
RBC membrane components. These include drug ad-
sorption onto the RBCs, neoantigen (“immune
complex”) formation, and induction of auto-
antibodies.19,21–23 IHA secondary to drug adsorption
occurs when IgG antibodies directed against the drug
interact with RBCs to which the drug is strongly
bound. The in vivo IgG-coated RBCs are then destroyed
in the reticuloendothelial system by extravascular
hemolysis. IHA due to neoantigen formation is thought
to occur when a drug binds weakly to normal RBCs
and the immune system perceives the drug-RBC
complex as foreign. Autoantibodies are directed
against membrane components and do not require the
drug for subsequent reactivity. These mechanisms can
be distinguished on the basis of serologic reactions of
the serum and the eluate (Table 1). The proposed
mechanisms are not mutually exclusive and may occur
in combination.21–23 In the majority of IHA cases due to
cefotetan, both the drug adsorption and the “immune
complex”mechanisms have been implicated.19
Our patient had clinical evidence of extravascular
hemolysis, characterized by slowly decreasing Hct,
absence of hemoglobinuria, and normal serum
haptoglobin. Immunohematology work-up confirmed
the presence of cefotetan-dependant antibodies. The
DAT was weakly positive for IgG. The patient’s serum
reacted with cefotetan-treated RBCs, supporting the
diagnosis of cefotetan-induced hemolytic anemia by
the drug adsorption mechanism. The antibody titer
was 4096 by saline IAT. This is in agreement with other
reports in the literature, as cefotetan antibodies have
been shown to be of high titer when compared with
other drug antibodies.19
IHA has been recognized in obstetric patients
receiving cefotetan prophylaxis during cesarean
delivery. Gallagher et al.4 published a case of a 27-year-
old woman who developed severe hemolytic anemia
10 days after cefotetan prophylaxis during cesarean
section. Mechanism of hemolysis involved both drug
adsorption and “immune complex” formation. The
patient eventually recovered after receiving steroids
and four units of PRBCs. Garratty et al.17 described six
obstetric patients receiving cefotetan prophylaxis for
cesarean section. Hemolytic anemia, requiring two to
seven PRBC transfusions, developed 9 to 14 days after
antibiotic prophylaxis. The drug adsorption and
“immune complex”mechanisms were implicated in all
their patients. Naylor et al.18 reported three additional
cases of cefotetan-induced hemolytic anemia following
cesarean delivery. Hemolytic anemia occurred 9 to 12
days after administration of cefotetan and was
confirmed in all patients by the drug adsorption,
“immune complex,” or both mechanisms. One patient
was treated with steroids,while another was transfused
with four units of PRBCs. The third patient received
Table 1 . Serologic characteristics of drug-induced hemolytic anemia
Drug Neoantigen
adsorption23 formation23 Autoantibody23 Patient
DAT
Polyspecific + + + +
IgG + Usually – + +
C3 Usually – + Usually – –
Serum Antibody
Routine – – +/– –
Soluble drug – + +/– –
Drug treated RBCs + – +/– +
RBC Eluate
Routine – – + –
Soluble drug – – + NT*
Drug treated RBCs + – + NT*
*Not tested
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steroids and four units of PRBCs. More recently,Arndt16
reported a 31-year-old woman who developed
hemolytic anemia 6 days after receiving two doses of
cefotetan for cesarean delivery. The patient required
transfusion with two units of PRBCs. Drug adsorption,
autoantibody formation, and “immune complex”
mechanisms were implicated. The patient had a
previous history of hemolytic anemia occurring after
cefotetan prophylaxis for cesarean delivery. The author
concluded that in retrospect, the earlier episode of
hemolysis may have also been due to an antibody to
cefotetan.
The diagnosis of cefotetan-induced hemolytic
anemia following prophylaxis for surgical procedures
may not always be obvious. An autoantibody (drug-
independent antibody) in a patient’s serum or eluate
may lead to an erroneous diagnosis of autoimmune
hemolytic anemia. Likewise, blood transfusion during
surgery may initially raise suspicion of a delayed
hemolytic reaction if the DAT is positive. Women are
predisposed to anemia during normal pregnancy,
because of a disproportionately increased plasma
volume compared with the RBC mass.24 Unless
excessive blood loss occurs during delivery, the Hct
generally increases in the immediate postpartum
period. When anemia occurs unexpectedly in the
postpartum period, if associated with the use of
antibiotics, immune-mediated hemolytic anemia should
be considered and investigated before more cefotetan
is given. In certain instances, the drug antibody can be
easily detected with minimal drug investigation
studies, such as the use of serum and titration studies as
demonstrated in our patient, while in others, a more
extensive drug study with the use of enzyme-treated
RBCs may be necessary.
Hemolytic anemia associated with cefotetan
prophylaxis usually becomes apparent about 7 to 10
days after administration.19 A single dose can result in
severe hemolytic anemia. The DAT can range from
weakly reactive to a strong (4+) reaction. In most cases,
the anemia resolves gradually, although the positive
DAT may persist for several weeks. Transfusion support
with PRBCs is indicated in the majority of patients.19
Because there is no universally accepted treatment
for cefotetan-induced IHA, the main goal is prevention.
Second- and third-generation cephalosporins have
been frequently associated with severe hemolytic an-
emia when compared with first-generation cephalo-
sporins.19 Indeed, there are only five well-documented
cases of hemolytic anemia attributed to first-generation
cephalosporins. Double-blind controlled trials in
obstetric and gynecologic surgery have demonstrated
no clear advantage of the more expensive broad-
spectrum agents over the first-generation cephalo-
sporins. For prophylaxis of infection in patients
undergoing obstetric surgery, cefazolin, a first-
generation cephalosporin, is associated with fewer
cases of IHA and may be preferable to cefotetan.25
Our case, in addition to others reported in the
literature, confirms the importance of considering
drug-induced hemolytic anemia whenever an obstetric
patient develops unexpected anemia following
antibiotic prophylaxis. This is especially true in cases
when the patient returns to the hospital 1 to 2 weeks
after receiving the prophylactic cefotetan. It is
important, once the diagnosis is established, that the
patient’s physician be informed and that the patient be
counseled not to receive cefotetan again.
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